The prospective significance of HIV-specific cytotoxic T lymphocyte (CTL) responses in highly exposed, persistently seronegative populations is unknown. In 1996-1997 we screened for CTL responses against HIV clade B Env in 39 recently enrolled Kenyan female sex workers, and followed these women prospectively. Annual HIV incidence was 5.8%. CTL were independently associated with age and recent HIV-1 exposure, but were not prospectively associated with protection in a multivariable model that included HIV-1 exposure and duration of sex work.
Some individuals remain HIV seronegative and immunologically normal despite repeated HIV-1 exposure. Although a minority harbour trace amounts of HIV-1 genetic material, suggesting productive infection below the limit of detection [1] , biological factors also play a role in sterile protection [2] . HIV-1-specific cytotoxic T lymphocytes (CTL) are important in viral control in HIV-1-infected individuals, but are unable to prevent eventual immunosuppression and death [3] . HIV-1specific CTL have been described in some HIV-1exposed, persistently seronegative (HEPS) populations, but not in others [4] , and it has been suggested that their detection might be a laboratory artifact [5] . Female sex workers (FSW) in the Pumwani slum of Nairobi, Kenya, have over 60 unprotected sexual exposures to HIV-1 per year, resulting in intense HIV-1 infection pressure [6] . Rates of HIV-1 seroconversion are highest during the first 3 years of cohort enrollment, although infection has been observed more than 10 years after enrollment [7] . Various HIV-1-specific immune responses have been detected in HEPS FSW from this cohort, including HIV-1-specific CD8 T cells [8] [9] [10] and HIV-1-Env-specific proliferative responses [10, 11] .
Between 1996 and 1997 we assayed for HIV-1-Envspecific CTL in newly enrolled (, 3 years) HIV-seronegative FSW, and followed these women in order to define the prospective significance of HIV-specific CTL. FSW were confirmed to be HIV-1 uninfected by a polymerase chain reaction system adapted to detect African clades [12] . Bulk CTL assays were performed as previously described [9, 10] by laboratory staff blinded to participant clinical and behavioural characteristics. phytohemagglutinin (PHA) blasts were infected with HIV-1 IIIB , inactivated with mitomycin C and used as autologous stimulators for bulk autologous peripheral blood mononuclear cells in IL-2 at a dilution of 10% (Lymphocult-T; Biotest, Solihull, United Kingdom). On day 10, autologous Epstein-Barr virus transformed B cells were infected overnight with either vSC8 (wild type vaccinia with the â-galactosidase gene) or vPE16 (HIV-1 clade B Env inserted into vSC8; obtained through the AIDS Research and Reference Reagent Program, NIAID, National Institutes of Health), and a 51 Cr release assay was performed in triplicate with effector to target (E : T) ratios of 50 : 1, 25 : 1, and 12.5 : 1. A positive assay was defined as the lysis of vPE16-infected targets 10% or greater than that of the control. All FSW were provided with free condoms, risk reduction counselling and sexually transmitted infection case management. Univariate analysis used one-way analysis of variance or the Mantel-Henszel chi-square test. Independent associations of CTL and HIV-1 acquisition were examined in multivariable models that included those variables associated in univariate analysis (P < 0.1) and in previous studies. Informed verbal consent was obtained from all study participants, and studies were approved by research ethics board (REB) at the University of Manitoba and the University of Nairobi.
All 39 newly enrolled seronegative FSW in follow-up during 1996-1997 were assayed, and followed for a total of 156.4 person-years (mean 4.0 years; range 0.1-6.5 years). CTL assays were performed at baseline only. At the time of the assay, participants had already been followed in the clinic for a mean of 1.0 years (range 0-2.0), and had practised sex work in any setting for a mean of 5.2 years (range 0.3-18). Their mean age was 32.2 years (range 21-42). Assuming a 30% HIV-1 seroprevalence in male clients [7] , and using selfreported client numbers and condom use, the number of unprotected HIV-1 exposures over the past year was calculated to be 42.3 (range 0.9-202.5). CTL directed against clade B HIV-1 Env were detected in eight out of 39 FSW (21%). CTL-positive FSW were older (35.9 versus 31.3 years; P ¼ 0.02), but had a similar duration of previous sex work (5.1 versus 5.3 years; P ¼ 0.9) and had been followed in the Pumwani cohort for a similar time (1.0 year for both; P ¼ 0.9). There was a trend towards higher HIV-1 exposure over the preceding year in the CTL-positive group (63.9 versus 36.4 exposures; P ¼ 0.2), and CTL-positive FSW were more likely to be taking an oral contraceptive [4/7 versus 5/30; likelihood ratio (LR) 4.5; P ¼ 0.04], and were less likely to be using injectable progesterone (0/7 versus 9/30; LR 4.4; P ¼ 0.04). Stepwise logistic regression (variables included: age, number of HIV-1 exposures over the past year, current use of oral contraception or injectable progesterone) demonstrated that only age and recent HIV-1 exposure were independently associated with CTL [LR 1.9, 95% confidence interval (CI) 1.1-3.6; P ¼ 0.03; and LR 1.04, 95% CI 1.0-1.07; P ¼ 0.05; respectively].
There were nine new HIV-1 infections during 156.4 person-years of follow-up, for an annual HIV-1 incidence of 5.8%. FSW who acquired HIV-1 reported a longer duration of previous sex work (9.5 versus 4.1 years; P ¼ 0.003). The presence of HIV-1-specific CTL at baseline was associated with a reduced subsequent risk of HIV-1 acquisition on univariate analysis (0/8 versus 9/31: LR 4.8; P ¼ 0.03), and there was a trend towards longer HIV-1-free survival in Kaplan-Meier analysis ( Fig. 1 : log-rank P ¼ 0.1). However, in Cox multivariable regression analysis (variables included: HIV-1 exposure over past year, previous duration of sex work, presence of HIV-1-specific CTL), only an increased previous duration of sex work was independently associated with seroconversion (risk ratio 1.2, 95% CI 1.0-1.3; P ¼ 0.02). There was no independent association between HIV-1 protection and baseline HIV-specific CTL (P ¼ 0.9).
The association of recent HIV-1 exposure with the detection of CTL by laboratory staff blinded to exposure data supports previous associations of expo-sure with HIV cellular immune responses [7, 13] , and strongly suggests that these responses were not a laboratory artifact. By following FSW prospectively, we attempted to clarify whether the CTL detected were responsible for HIV-1 protection, or were perhaps induced/maintained by the non-productive HIV exposure, with other factor(s) actually mediating protection. Although baseline CTL were associated with a reduced HIV incidence in univariate analysis, this association fell out in a multivariable model that included the duration of previous sex work and levels of HIV exposure. Our sample size was moderate, with 156 person-years of follow-up and a relatively low HIV-1 incidence of 5.8%, perhaps as a result of effective socio-behavioural interventions [14] , so a causal association between CTL and HIV protection cannot be excluded. However, an alternative hypothesis is that CTL are the result of non-productive HIV-1 exposure, rather than mediators of protection. This might explain the low magnitude of HIV-specific CD8 responses in HEPS cohorts, compared with those seen in HIVinfected individuals [15] . The only definitive way to resolve the issues of CTL and HIV-1 protection is to induce similar responses in the context of a randomized vaccine trial, which is the aim of several HIV-1 vaccines in development [16, 17] . IL-7 and Flt-3L plasma levels are increased during highly active antiretroviral therapy-associated IL-2 therapy Stéphanie Beq a , Arnaud Fontanet b , Jacques Theze a and Jean-Hervé Colle a IL-2 is used in conjunction with highly active antiretroviral therapy to increase the CD4 cell count in HIV-positive patients. The mechanisms involved remain ill-defined. Here we show that during the first cycle of IL-2 therapy, IL-7 and Flt-3L plasma levels are increased, whereas levels of stem cell factor are unchanged. This supports the hypothesis that aside from stimulating CD4 T cells IL-2 may also indirectly affect lymphocyte production through the stimulation of lymphopoietic cytokines.
In combination with highly active antiretroviral therapy (HAART), the administration of IL-2 in HIV patients leads to a substantial and sustained expansion of the CD4 T-cell pool [1] . Most of the studies in this field were performed in patients with relatively high baseline CD4 cell counts. As the number of CD4 lymphocytes is a major factor in the occurrence of opportunistic infections, we also studied the effects of IL-2 administration in patients whose CD4 cell counts remained low (CD4 ,200 cells/mm 3 ) after one year of HAART, despite the efficient control of viral load. We observed that IL-2 combined with HAART in these patients rapidly increased the CD4 cell count [2] .
The in-vivo mechanism of action of IL-2 is not well understood. In agreement with the well defined in-vitro properties of IL-2, it was first proposed that the increase in CD4 T cells is caused by a direct effect of IL-2, i.e. the expansion of peripheral pre-existing CD4 T cells. This is supported by the fact that during IL-2 administration a pronounced increase in naive CD4 T-cell proliferation was observed as measured by ex-vivo labelling with 5-bromodeoxyuridine and by staining for Ki67 [1] . In our study, after three cycles of IL-2, the decreased death of CD4 lymphocytes correlated with the increased expression of Bcl-2, thus suggesting that IL-2 antiapoptotic effects may also participate in increasing CD4 cell counts [2] . Alternatively, it could be suggested that the preferential expansion of CD4 þ CD25 þ cells recovered in HAART plus IL-2-treated patients [3] may also result from an indirect and long lasting stimulation of lymphopoiesis. This would explain why CD4 cell counts remain high after IL-2 therapy has been withdrawn. Cytokines known to affect lymphopoiesis may participate in this mechanism. IL-7, by its action on lymphoid precursor cells and on thymopoiesis, plays a critical role in the maintenance of T-lymphocyte numbers and clonal T-cell diversity [4] . Flt-3L (ligand of Fms-like tyrosine kinase 3) and stem cell factor (SCF), originally identified as haematopoietic factor, may also participate in increasing the number of thymic precursors [5] .
To test this second hypothesis, we carried out a retrospective evaluation of IL-7, Flt-3L and SCF plasma levels in samples obtained in the course of the clinical trial mentioned above. The patients, treatment, and results obtained after three IL-2 cycles have been described previously [2] . Briefly, 11 patients received several cycles of IL-2 (4.5 3 10 6 IU subcutaneously twice a day for 5 days followed by a 5-week rest period). At the end of the third IL-2 cycle, CD4 cell counts had increased by at least 100%. Here, we report on the analysis of the first IL-2 cycle since cytokine production during this period that is more likely to be directly dependent on IL-2 administration.
Changes in CD4 cell counts over the first cycle are shown in Fig. 1a . At the end of the 5-day IL-2 administration period, CD4 T cells briefly decreased in number. The origin of this CD4 cell decrease is unknown (activation followed by changes in traffick-
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Days of IL-2 cycle
Days of IL-2 cycle IL-2 treatment during the cycles consisted of 4.5 3 10 6 IU subcutaneously twice a day for 5 days followed by a 5-week rest period. Blood was collected before IL-2 administration and from days 5 to 42 of the first IL-2 cycle. The grey area shows the days of IL-2 administration. CD4 and CD8, polymorphonuclear cells, monocytes and erythrocytes were counted in whole blood. IL-7, Flt-3L and stem cell factor plasma levels were determined by specific immunoassays. Vertical bars indicate SE. For reference, mean (AE SE) plasma values in healthy individuals were as follows: IL-7: 1.5 (AE 0.9) pg/ml (N ¼ 15); Flt-3L: 72 (AE 5) pg/ml (N ¼ 23) and stem cell factor: 864 (AE 156) pg/ml (N ¼ 23). P values refer to differences between levels on day 1 and those observed during follow-up (days 5, 14, 28, and 42) (Wilcoxon signed-rank test). Only significant differences are indicated.
ing, apoptosis, etc.). After IL-2 discontinuation, the CD4 cell count rose to a peak on day 14 and slowly declined thereafter. CD8 lymphocytes followed the same pattern (Fig. 1e ). In contrast to T lymphocytes, blood monocytes such as polynuclear leucocytes increased in number by day 5, but rapidly returned to baseline after the end of the IL-2 injections. Red blood cell counts were unchanged, indicating that the leucocyte count variations observed were not the consequence of blood volume changes ( Fig. 1f,g,h) .
Mean (AE SE) baseline IL-7 serum levels corresponded to 4.8 (AE 3.5) pg/ml ( Fig. 1b) . Thereafter, IL-7 levels peaked on day 5 (8.8 pg/ml AE 5.3), before declining and returning to baseline levels after day 28. In comparison with day 1, IL-7 levels were marginally different on day 5 (P ¼ 0.06), and significantly different on day 14 (P ¼ 0.04). Similarly, IL-7 serum levels remained elevated during the second and third cycles (data not shown). Flt-3L followed a similar pattern to IL-7, increasing from a baseline level of 118 (AE 60.6) to a maximum of 195 (AE 79.3) on day 5 (P ¼ 0.002) before returning to baseline levels by the end of the cycle. Interestingly, IL-7 levels peaked either on day 5 or on day 14 depending on the patient, whereas Flt-3L peaked systematically on day 5 for all patients. In contrast to IL-7 and Flt-3L, SCF levels did not vary during IL-2 treatment.
Our data raise several issues. First, the mechanism of IL-7 induction: the kinetics study indicates that IL-7 is at its most elevated when CD4 cell counts were lowest on day 5. Given that increased levels of IL-7 have been observed in several lymphopenias of different aetiologies, it has been suggested that peripheral CD4 cell levels participate in the control of IL-7 secretion and that both parameters are part of a feedback regulatory loop [4] . In this context, the decreased CD4 cell counts on day 5 may be responsible for an increase in plasma IL-7. Alternatively, IL-2 may directly induce IL-7 production by bone marrow, thymic stroma cells or dendritic cells from lymphoid organs.
Second, the role of IL-7 in CD4 T-cell count recovery: IL-7 may participate in increasing the CD4 cell count by inducing thymic production and output. In a recent IL-2 clinical trial, thymic involvement in naive T-cell recovery was suggested after quantifying T-cell receptor rearrangement excision circles [6] . In addition, the IL-7 increase may in conjunction with IL-2 induce or extend the expansion and survival of peripheral CD4 T cells.
Third, the potential role of Flt-3L production during IL-2 immunotherapy: Flt-3L production may result from Tcell stimulation as it has been shown that cytokines sharing the ª1 c receptor subunit, such as IL-2 and IL-7, induce resting T cells to produce Flt-3L. Upon IL-2 administration, Flt-3L may boost the mobilization of precursor cells from bone marrow, thus explaining the short-term increase in blood monocytes and polynuclear cells.
Finally, Flt-3L in synergy with IL-7 is likely to stimulate the production of thymic progenitor cells [5] , which in turn would also lead to an increase in CD4 T-cell numbers.
In conclusion, our study provides new clues in understanding the in-vivo mechanism of the action of IL-2.
The data suggest that aside from the direct effect of IL-2 on the peripheral T-cell pool it may also indirectly affect myelopoiesis and lymphopoiesis.
plasma concentrations and non-nucleoside reverse transcriptase (NNRTI) resistance mutations on the antiviral activity of efavirenz in patients experiencing early virological failure under nevirapine-containing regimens. Up to 41% of patients reach less than 50 copies/ml at 48 weeks. No association was found between the presence of NNRTI resistance mutations and virological outcome. Nevertheless, patients responding virologically and carrying NNRTI-resistant viruses had higher efavirenz levels than those who did not respond.
Non-nucleoside reverse transcriptase inhibitors (NNRTI) show high antiviral activity against HIV-1 infection, and indirect evidence suggests that efavirenz is particularly potent [1] [2] [3] . Nevertheless, the development of single mutations at critical sites within the reverse transcriptase gene can reduce or even annul NNRTI activity. It is generally believed that broad cross-resistance between NNRTI is the main factor limiting their sequential use [4] . This is particularly true in patients failing for long periods of time on NNRTIbased regimens, when the accumulation of multiple mutations occurs. Nevertheless, both in-vitro and invivo studies have suggested that efavirenz could be effective against HIV-1 strains carrying some NNRTI resistance mutations [5, 6] . On the other hand, efavirenz plasma concentrations have been shown to influence the virological response to NNRTI-based regimens [7] .
The aim of this study was to determine whether the use of efavirenz in patients showing early virological failure under a nevirapine-based regimen may allow them to regain complete viral suppression. The role of both efavirenz plasma levels and NNRTI resistance mutations in the effectiveness of this intervention was also analysed.
For this purpose, 48 patients who showed plasma viral load rebound over 50 HIV-RNA copies/ml (confirmed in two separate specimens collected 2 weeks apart) after being undetectable for at least 3 months under a nevirapine-based triple combination (nevirapine, 200 mg twice a day) were selected. Nevirapine was substituted by efavirenz (600 mg a day) keeping the same two nucleoside reverse transcriptase inhibitors (NRTI) as backbone.
The plasma HIV-RNA level was determined using the third-generation branched DNA assay. Measurements were performed at baseline, 3, 6 and 12 months after replacing nevirapine by efavirenz. A significant virological response was defined when the plasma viral load reduction was over 1 log or reached less than 50 HIV-RNA copies/ml. Nevirapine plasma concentrations were determined before the morning dose intake (C trough ) using a validated high-performance liquid chromatography method with ultraviolet detection [8] . Efavirenz plasma concentrations were determined at a median time of 12 h after the night dose intake using the same highperformance liquid chromatography method as for nevirapine.
HIV-1 reverse transcriptase genetic sequences were obtained at baseline using an automatic sequencer (ABI 3000; Applied Biosystems, Foster city, CA, USA). Drug resistance genotypic interpretation was performed according to the latest International AIDS Society USA resistance guidelines (www.iasusa.org) and expert advice. Resistance to efavirenz was considered in the presence of either K103N or Y188L, or when two or more other NNRTI resistance mutations were present. Resistance to nevirapine was considered in the presence of any NNRTI resistance mutation recorded in the International AIDS Society USA list.
Statistical analyses were performed using SPSS version 9.0 (SPSS Inc., Chicago, IL, USA), using either parametric or non-parametric tests as needed. Significance was considered for P values below 0.05.
At the time of first virological failure on nevirapine, patients had been exposed to the drug for a median (range) time of 7.4 months (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The median (range) plasma viral load was 4313 (72-45 148) HIV-RNA copies/ml. A total of 29 of 35 subjects (83%) for whom genetic material could be amplified and sequenced harboured one or more NNRTI resistance mutations. The median (interquartile range; IQR) nevirapine C trough at the time of viral rebound was 3.6 ìg/ml (2.4-4) . Interestingly, patients lacking NNRTI resistance mutations (six out of 35) at the time of viral rebound had lower nevirapine C trough [median (IQR) 3.4 ìg/ml (2.05-4.05) versus 0.03 ìg/ml (0-3.4)], although this difference did not reach statistical significance (P ¼ 0.058).
After replacing nevirapine by efavirenz, a significant virological response was recorded in 20 (41.7%), 23 (48%) and 20 (41.7%) patients at weeks 12, 24 and 48, respectively (intent-to-treat analysis). An undetectable plasma viral load (, 50 copies/ml) was reached in 25, 39.6 and 41.7% of subjects at weeks 12, 24 and 48, respectively. The plasma viral load reductions from baseline to each timepoint are recorded in Table 1 .
It should be pointed out that in our study there were no discontinuations of therapy as a result of efavirenzrelated adverse effects, although two individuals complained of dizziness and one of vivid dreams plus insomnia. Nevertheless, symptoms tended to solve spontaneously after the first weeks on therapy.
When efavirenz-associated resistance mutations were considered, no association between their presence and the virological response was found at any timepoint. In contrast, efavirenz plasma concentrations were higher in virological responders at any timepoint with respect to non-responders (see Table 1 ). Moreover, patients who attained a significant virological response at week 12 despite carrying efavirenz-associated resistant strains had significantly higher efavirenz plasma concentrations than those who did not respond [median (IQR) 3.6 ìg/ml (2.8-6.4) versus 2.7 ìg/ml (1.4-2.9); P ¼ 0.027, respectively].
A positive significant correlation was found at week 12 between efavirenz plasma concentrations and˜log plasma viral load (r ¼ À0.4; P ¼ 0.007). This significant correlation was still present at week 48, although in to a lesser extent (r ¼ À0.41; P ¼ 0.03).
At week 12, 75% of patients carrying viruses with efavirenz-associated resistance mutation strains and efavirenz plasma levels greater than 3 ìg/ml showed a significant virological response. In contrast, it occurred in only 22% of patients showing efavirenz plasma levels of less than 3 ìg/ml. This critical threshold for efavirenz plasma concentrations associated with the chance of attaining a significant virological response was also confirmed at weeks 24 and 48 (79 versus 40%; P ¼ 0.03; and 76.4 versus 41.6%; P ¼ 0.03; respectively).
Our results demonstrate that complete and sustained viral suppression lasting up to 48 weeks is feasible in up to 41% of patients who showed early virological failure under a nevirapine-based regimen. This benefit of taking efavirenz was independent of the presence of NNRTI resistance mutations. Nevertheless, the initial response to this intervention was mainly driven by efavirenz plasma concentrations. The attainment of adequate efavirenz plasma levels (. 3 ìg/ml) in the early stages of the intervention was associated with the chances of virological success. Hypothetically, high efavirenz plasma concentrations could overcome resistance in a relatively large proportion of patients failing nevirapine.
On the other hand, virological failure to nevirapinebased regimens was almost always caused by the selection of NNRTI resistance mutations. Only 17% of patients lacked resistance mutations at the time of failure, and as expected most of these individuals were not compliant and showed low or undetectable nevirapine plasma trough levels.
In summary, therapeutic drug monitoring of nevirapine plasma concentrations at the time of the first viral rebound could help to identify those patients who may benefit from interventions focused on improving drug adherence or alternatively to attempt a rescue inter-Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Table 1 . Plasma viral load changes (˜log plasma viral load) and efavirenz plasma concentrations at weeks 12, 24 and 48.
Week 12
Week 24
Week 48 Values are expressed as median and interquartile ranges.
vention based on efavirenz. In the latest situation, therapeutic drug monitoring of efavirenz plasma concentrations could help to optimize the efavirenz dose in an attempt to overcome resistance. Over the past 5 years, 1846 HIV-infected patients underwent drug resistance testing at our institution. None out of 216 drug-naive subjects showed K65R. However, it was recognized in 53 out of 1630 antiretroviral-experienced patients (3.3%), of whom 10 had never been exposed to tenofovir. The rate of K65R increased from 0.6% in 1999 to 11.5% in 2004. The recognition of K65R corre-lated negatively with the presence of thymidine analogue mutations but positively with Q151M.
High rates of early virological failure associated with the emergence of the K65R mutation at the HIV-1 reverse transcriptase gene have recently been reported among HIV-infected patients on tenofovir-containing triple nucleos(t)ide regimens [1] [2] [3] . Data from large genotypic databases have shown that K65R is quite uncommon, although its rate might be increasing. K65R is selected in vitro by tenofovir, zalcitabine, didanosine, stavudine and abacavir [4, 5] . In vivo, tenofovir, abacavir and didanosine have been shown to select the K65R mutation [5] . Although K65R reduces the susceptibility to tenofovir and to a lesser extent affects the activity of other nucleoside analogues such as abacavir, didanosine and lamivudine [5] , it retains the activity of zidovudine. Therefore, viruses carrying K65R show broad cross-resistance to nucleos(t)ide reverse transcriptase inhibitors.
Data about the rate of K65R and its association with other nucleoside analogue resistance mutations are scarce. Herein, we describe the rate of K65R in a large database of genotypic drug resistance reports in a reference hospital in Madrid, Spain. Its association with other reverse transcriptase resistance mutations is further described.
All plasma samples referred to our reference laboratory for drug resistance testing over the past 5 years were examined. A total of 1846 specimens with genotypic reports were analysed. They were drawn from 216 drug-naive and 1630 treatment-experienced HIV-infected patients.
A total of 53 specimens showed K65R, providing an overall rate of 2.9%. None of drug-naive individuals showed K65R. The rate of K65R significantly increased over time among treatment-experienced patients, from 0.6% in 1999 to 11.5% in the first trimester of 2004 ( Fig. 1) .
Although K65R was identified mainly in individuals failing tenofovir-based combinations, it was also recognized in 10 patients never exposed to tenofovir. The latter were receiving stavudine plus didanosine (four), abacavir plus lamivudine (two), stavudine plus lamivudine (two), stavudine plus abacavir (one) and zalcitabine (one) at the time of resistance testing. The remaining 43 subjects carrying K65R were failing different tenofovir-based combinations: tenofovir plus didanosine (32), tenofovir plus abacavir (six), tenofovir plus lamivudine (four) and tenofovir alone (one).
The rate of thymidine analogue mutations (TAM) was significantly lower among patients harbouring K65R with respect to the rest. Whereas TAM appeared in 60.1% of plasma specimens collected from treatmentexperienced patients lacking K65R, they were present in only 12 out of 53 with K65R (22.6%; P , 0.0001). Moreover, only K70R or the uncommon K219E were seen along with K65R. No patients with K65R viruses harboured more than these two TAM.
In the univariate analysis, the presence of K65R was associated with the absence of M41L (P , 0.0001), E44D/A (P ¼ 0.0013), D67N (P , 0.0001), L210W (P , 0.0001) and T215Y/F (P , 0.0001). In contrast, K65R was associated with the presence of V75I (P , 0.0001), Y115F (P , 0.0001) and the Q151 complex (P , 0.0001). In the multivariate analysis, the presence of K65R was inversely associated with the number of TAM [odds ratio (OR) 0.54; 95% confidence interval (CI) 0.24-0.54] and with the presence of T215Y/F (OR 0.09; 95% CI 0.01-0.9), whereas it was positively associated with the presence of Q151M (OR 4.82; 95% CI 1.76-13.22) and the total number of other nucleoside analogue resistance mutations distinct of TAM (OR 1.59; 95% CI 1.25-2.02). Of note was the fact that the M184V mutation accompanied K65R in 24 cases (45%). However, no association was found between the presence of K65R and M184V, although a trend towards its concomitant appearance was noted (P ¼ 0.1).
As other groups have shown [6] , the selection of K65R is significantly associated with the use of tenofovir. The incidence of this mutation has increased in recent times, presumably as a result of the increasing use of tenofovir in clinical practice. However, as was shown in our study, other nucleoside combinations may also favour the selection of K65R, although it appears to occur more rarely. In our analysis, K65R was particularly frequent among patients failing tenofovir/didanosine-based combinations, but this may indirectly reflect the fact that a large group of patients in our institution have been exposed to this combination during the past 2 years.
We found a reciprocal exclusion between TAM and mutation K65R. They may represent divergent and antagonistic pathways driving to nucleoside analogue resistance. Moreover, only two TAM (K70R and K219E) were seen along with K65R. Codon 219 changes seem to be the only TAM tolerated by K65R, whereas a clear negative interaction seems to exist with codon 41 and 215 mutations. Of note was the fact that all our cases with codon 219 changes showed a specific amino acid substitution (K219E), whereas other changes (K219Q and K219N) , which are frequently seen with other TAM, never appeared with K65R.
Previous studies have claimed that the Q151M complex might be associated with K65R [7] . This association may be clinically relevant, because tenofovir seems to preserve its activity in the presence of Q151M alone but not when K65R is also present. Viruses harbouring Q151M along with the K65R mutation are highly resistant to all nucleoside analogues. In our study, 10 out of 53 patients with K65R had Q151M.
The frequent selection of M184V along with K65R results in a novel multi-nucleoside-resistant genotype [8] , although it may provide in vitro an increased susceptibility to zidovudine and perhaps to stavudine [5] . Clinical data are needed to clarify to what extent the K65R+M184V genotype compromises the activity of nucleoside analogues. This information may be particularly relevant given that tenofovir is now widely used with lamivudine, and single pills containing tenofovir and emtricitabine are expected to be available soon.
In conclusion, the rate of K65R has increased significantly over the past 5 years among treatment-experienced patients, and currently is above 10%. This fact is directly related to the wide use of tenofovir in clinical practice. Given the antagonism between K65R and TAM, further clinical studies assessing the benefit of using combination nucleoside analogues driving these different resistance pathways should be conducted. 
Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype Cinfected seronegative women
Cecilia Rademeyer a , Joanne H van Harmelen a , Gita Ramjee b , Salim S. Abdool Karim c and Carolyn Williamson a Viral population diversity was assessed in samples collected from five HIV-infected women who were RNA positive and antibody negative. Similar to studies in men, highly conserved viral variants were detected (mean nucleotide diversity of 0.11% for p17p24, 0.32% for C2C3). In two individuals diversity was uncharacteristically lower in env C2C3 than in gag p17p24, suggesting selection in env at this very early stage of infection.
Although transmitted HIV-1 diversity has implications for the design of interventions such as vaccines and microbicides, this has been understudied, particularly in women. The majority of available data on virological determinants impacting on sexual transmission are derived from investigations on recently infected men showing homogeneous viral population transmission, even when donors harboured genetically complex viral populations [1] [2] [3] [4] [5] . The limited number of studies performed on women suggest sex differences, showing that women could be more susceptible to infection with multiple HIV-1 variants compared with men [1, [6] [7] [8] [9] .
Most transmission studies have investigated HIV antibody-positive individuals; however, these may not accurately reflect the original transmitted population as diversification may occur from the time of infection to seroconversion as a result of host selective pressures and high viral turnover [10] . This study characterized HIV-1 env and gag populations during the pre-seroconversion stage in heterosexually infected South African female sex workers. These samples provide unique and valuable insights into the mechanisms of transmission and early replication during primary subtype C HIV-1 infection of women.
Samples were obtained from a female sex worker cohort screened monthly for seroconversion [11] . The date of infection was estimated as the midpoint between the last RNA-negative and the first RNApositive sample, except for Du23 in which the date of infection was estimated as 14 days before the first RNA-positive sample. For our retrospective study, samples from two visits before the seroconversion sample were screened for HIV RNA using the nucleic acid sequence-based amplification (NASBA) viral load assay. RNA was extracted and a reverse transcriptasenested polymerase chain reaction (PCR) was performed for amplification of both the env C2C3 (511 base pairs; bp) and gag p17p24 (621 bp) regions. PCR-based limiting dilution assays were performed to ensure that the number of template copies in a single reverse transcriptase-nested PCR reaction were sufficient to ensure that the analysis of 20-40 colonies would be representative of the majority of viral populations (minimum of 30 copies) [12, 13] . The amplifiable copy number per sample ranged from more than 32 (n ¼ 1) to over 320 (n ¼ 4) was calculated using QUALITY (Quantitation Using A LImiting diluTion assaY) [13] . Env C2C3 and gag p17p24 diversity was assessed using the heteroduplex tracking assay (HTA) [14] . Two clones representing each HTA migration pattern were sequenced and sequences were analysed using distance-based phylogenetic methods. Intra-individual diversity was calculated by adjusting the sequence ratio to reflect the migration pattern frequency and DNA distances were expressed as a percentage of nucleotide diversity using the Kimura 2-parameter model. The phenotype was predicted using two different methods [15, 16] .
Five HIV-seronegative women (Du23, 114, 145, 204 and 421) were identified as HIV-1 RNA positive, all of whom seroconverted within a month of HIV-1 RNA identification. Samples were collected from individuals infected for an estimated 7 days (Du114, Du204) to 14 days (Du23, Du45, Du421). Characteristic of acute infection, the plasma viral loads were high, ranging from 1.6 3 10 4 ; 3.9 3 10 4 ; 9.3 3 10 4 ; 5.6 3 10 5 to 5.1 3 10 6 copies/ml for Du23, 145, 204, 114 and 421, respectively.
Four out of five individuals produced HTA heteroduplexes exhibiting very little to no shifts (Fig. 1a,c) in both the p17p24 as well as the C2C3 region. In one individual, Du204, four different p17p24 intermediary shift heteroduplex migration patterns were observed (Fig. 1b) . In the C2C3 region, Du145 exhibited two different heteroduplex migration patterns (Fig. 1d) , the result of a 6 bp insertion (intermediary shift) and 99 bp deletion (large shifts) in 5 and 15% of the viral population, respectively. Unlike C2C3, p17p24 sequence analysis showed no insertions or deletions.
The mean intra-individual p17p24 DNA distances ranged from 0.06 to 0.2% (overall mean 0.11%), with a maximum nucleotide distance of 1.2%. The mean C2C3 intra-individual diversity ranged from 0.02 to 0.6% (overall mean 0.32%), with a maximum distance of 1.8%. Interestingly, in Du114 and Du204, mean intra-individual diversity was uncharacteristically lower in C2C3 (0.02 and 0.1%, respectively) than in p17p24 (0.08 and 0.2%, respectively).
All env and gag sequences grouped within subtype C and no evidence of dual infection was detected (results not shown). The phenotype was predicted to be R5 in all cases.
In conclusion, recently infected women in the preseroconversion period of infection harboured highly homogeneous, but not identical, viral populations. The genetic distance between viruses infecting an individual exceeded the expected rate of diversification considering the short time from transmission (as much as 1.8% in C2C3 and 1.2% in p17p24) and indicates selective intraperson transmission of multiple closely related variants. The viral populations in recently infected women in this study were highly homogenous compared with other studies in women. This region of the genome is quite heterogeneous; our study showed a mean inter-individual genetic diversity of 8.6% for C2C3 and 7. sity from this study to a similar investigation in women showed the overall median C2C3 difference of 0.4% for our study, compared with 1.2% in the Kenyan study [6, 7] . It would be of interest to extend the current study to include the V1 to V5 region, as this would enable more extensive comparisons with other studies carried out in women and men [17] . Whereas the choice of sample (that is DNA versus RNA) may have influenced the results, it is unlikely to have influenced the conclusion of this study, as the time available for diversification of archival DNA is short. There are multiple host and viral factors that could account for the observed differences in transmitted variants between these studies: the presence of ulcerative sexually transmitted infections, contraception use [18] , as well as differences in the predominantly circulating subtypes, A and D in Kenya, and C in South Africa.
Two women, sampled within 7 days post-infection, had unexpected lower diversity in env compared with gag, suggesting that very early selection forces were focussed on properties in envelope. This supports cell tropism or viral fitness as playing a major role in the selective transmission of variants resulting in reduced env diversity. Early cytotoxic T-cell lymphocyte immunological selection pressure could have resulted in diversification in gag. It is likely that selective transmission and selective amplification both contribute to this early viral population selection and restriction. An understanding of the mechanisms governing transmission could assist in the planning and design of much needed interventions such as vaccines and microbicides.
